Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit [Yahoo! Finance]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Yahoo! Finance
The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims Valadez alleged that her cancer resulted from taking over-the-counter Zantac and its generic versions from 1995 to 2014. Her attorneys sought $640 million for her suffering, arguing that Zantac's active ingredient, ranitidine, could transform into the cancer-causing substance NDMA under certain conditions. However, the judge did not allow Valadez to seek punitive damages. GSK Plc (NYSE: GSK ) and Boehringer Ingelheim argued that scientific evidence did not support claims that Zantac causes cancer. During the trial, Valadez's attorneys argued that the companies knew about the risks of ranitidine turning into NDMA but did not ensure proper handling by transporters, distributors, and stores. Reuters noted that attorn
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (GSK): Did This Healthcare Stock Show a Strong Performance in Q1? [Yahoo! Finance]Yahoo! Finance
- CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK [Yahoo! Finance]Yahoo! Finance
- GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.MarketBeat
- US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased RiskBusiness Wire
GSK
Sec Filings
- 6/24/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 6-K
- GSK's page on the SEC website